Skip navigation
  •  Inicio
  • UDC 
    • Cómo depositar
    • Políticas do RUC
    • FAQ
    • Dereitos de Autor
    • Máis información en INFOguías UDC
  • Percorrer 
    • Comunidades
    • Buscar por:
    • Data de publicación
    • Autor
    • Título
    • Materia
  • Axuda
    • español
    • Gallegan
    • English
  • Acceder
  •  Galego 
    • Español
    • Galego
    • English
  
Ver ítem 
  •   RUC
  • Facultade de Ciencias da Saúde
  • Investigación (FCS)
  • Ver ítem
  •   RUC
  • Facultade de Ciencias da Saúde
  • Investigación (FCS)
  • Ver ítem
JavaScript is disabled for your browser. Some features of this site may not work without it.

Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance

Thumbnail
Ver/abrir
Cid_Clinical.pdf (248.0Kb)
Use este enlace para citar
http://hdl.handle.net/2183/19670
Coleccións
  • Investigación (FCS) [1295]
Metadatos
Mostrar o rexistro completo do ítem
Título
Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance
Autor(es)
Cid-Silva, Purificación
Llibre, Josep M.
Fernández-Bargiela, Noelia
Margusino-Framiñán, Luis
Balboa-Barreiro, Vanesa
Pernas, Berta
Martín-Herranz, Isabel
Castro-Iglesias, Ángeles
Poveda, Eva
Data
2017-07-16
Cita bibliográfica
Cid-Silva P, Llibre JM, Fernández-Bargiela N, et al. Clinical experience with the integrase inhibitors Dolutegravir and Elvitegravir in HIV-infected patients: efficacy, safety and tolerance. Basic Clin Pharmacol Toxicol. 2017;121(5):442-446
Resumo
[Abstract] Two integrase inhibitors (INSTIs), dolutegravir (DTG) and elvitegravir/cobicistat (EVG/COBI), have joined recently the pharmacotherapy arsenal against HIV. This study evaluated the efficacy and tolerability of these INSTIs in the last two years. A retrospective observational study in patients who started DTG or EVG/COBI from January 2015 to January 2017 at a reference hospital in north-western Spain was done. Epidemiological, clinical and immunovirological data were recorded. A statistical analysis was performed with SPSS software. A total of 542 DTG (n = 275)- or EVG/COBI (n = 267)-based therapies were initiated during the study period. Overall, more than 90% of naïve and pre-treated patients had virological suppression in both groups after 48 weeks of initiation of treatment per-protocol snapshot analysis. During follow-up, 10.2% of patients were treated with DTG and 4.5% of those treated with EVG discontinued due to adverse events (AE). In the case of DTG mainly related to neuropsychiatric disturbances (70.4%) and for EVG/COBI with gastrointestinal discomfort (50%). Female sex [HR 2.255 (95%CI 1.121–4.535), p = 0.023] and DTG treatment [HR 2.453 (95%CI 1.221–4.931), p = 0.012] were associated with AE discontinuations. Specifically for neuropsychiatric events, DTG treatment [HR 5.906 (95%CI 1.954–17.846), p = 0.002] and receiving abacavir/lamivudine/DTG [HR 4.380 (95%CI 1.348–14.233), p = 0.014] were identified as predictive risk factors for treatment discontinuations in two different multivariate analyses. A high percentage of AE discontinuations not previously described in clinical trials has been observed, especially with DTG. Female gender and DTG treatment were identified as risk factors for AE discontinuation. DTG-based therapies, especially in combination with abacavir/lamivudine, were associated with an increased risk of treatment discontinuation due to neuropsychiatric AE.
Versión do editor
http://dx.doi.org/10.1111/bcpt.12828
Dereitos
This is a peer reviewed version of the article which has been published in final form at Wiley Online Library. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for self-archiving.
ISSN
1742-7835
1742-7843
 

Listar

Todo RUCComunidades e colecciónsPor data de publicaciónAutoresTítulosMateriasGrupo de InvestigaciónTitulaciónEsta colecciónPor data de publicaciónAutoresTítulosMateriasGrupo de InvestigaciónTitulación

A miña conta

AccederRexistro

Estatísticas

Ver Estatísticas de uso
Sherpa
OpenArchives
OAIster
Scholar Google
UNIVERSIDADE DA CORUÑA. Servizo de Biblioteca.    DSpace Software Copyright © 2002-2013 Duraspace - Suxestións